Tempus, Genmab Collaborate on Cancer Biomarker Discovery

Tempus, Genmab Collaborate on Cancer Biomarker Discovery

Publication date: Sep 09, 2019

Genmab said today that it has entered into a strategic collaboration with Tempus to apply artificial intelligence to biomarker and target discovery in oncology.

Concepts Keywords
Artificial Intelligence Medicine
Biomarker Clinical medicine
Oncology Biomarkers
Biology
Genmab
Artificial intelligence

Semantics

Type Source Name
drug DRUGBANK Nonoxynol-9
disease DOID Cancer
disease MESH Cancer

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *